Carisma Therapeutics Inc. has entered into a subscription agreement with Ocugen, Inc. as part of a private placement transaction. The agreement involves Carisma issuing and selling $5.0 million worth of shares of its Common Stock to Ocugen. The exact number of shares and the price per share will be determined by dividing the Aggregate Valuation by the Post-Closing Parent Shares as outlined in the Merger Agreement. Further details will be available in Carisma's upcoming quarterly report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Carisma Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-085705), on August 29, 2025, and is solely responsible for the information contained therein.